Mickaël Guyot

Sales Specialist in the West and South region of Europe @ Merck Life Science

About

As an experienced pharmacist with over 15 years in the pharma industry, I create partnerships with biotech and pharma customers to support their pipelines for small molecule, drug conjugate, highly potent APIs (HPAPI), antibody drug conjugates (ADC), and complex APIs. My commitment to full transparency enables me to bring technical innovations and solutions that meet my partners' expectations. If you're interested in fully leveraging Millipore CDMO capabilities to support your goals, feel free to contact me at mickael.guyot@merckgroup.com or +336 66 15 27 93 to schedule a call.

Country

City

France

Industry

Pharmaceuticals

Skill

Microsoft Office, Customer Service, Management, Microsoft Excel, Project Management, Strategic Planning, Leadership, Microsoft Word, Research, Logistics Management

Experience

Sales Specialist in the West and South region of Europe

Merck Life Science

2021-12 - Present · 4 yrs 10 mos

France

In principle we are doing the following: *Service under non GMP and cGMP ( from preclinical to commercial) *Highly Potent API synthesis ( HPAPI). *Development and manufacture of Antibody Drug Conjugaison ( ADC). *Activated Polyethylene Glycol (aPEG). *Custom API synthesis

Business Development Specialist

Eurofins CDMO

2018-9 - 2021-12 · 3 yrs 4 mos

Saint Gely du Fesc

Customer portfolio development Technical evaluation on primary and secondary packaging Benchmarking

Trials Supply Operation Manager Consultant ALTRAN

Sanofi

2017-6 - 2018-9 · 1 yr 4 mos

Région de Montpellier, France

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone: Study set up : Protocole, Monitoring Plan,IND and IMPD review Management of Investigational Médicinal Product : Production and packaging plan IMP needs forecast / Labeling / Traceability

Clinical Operation

Innate Pharma

2016-3 - 2017-5 · 1 yr 3 mos

Marseille Area, France

Double blind placebo Phase 2 study, 153 patients with Acute Myeloid Leukemia : Monitoring visit / Monitoring visit report / Follow up / Report Monitoring Pharmacy Quality Control of Trial Master File Eudra CT report Database cleaning Management double blind end of study phase II Pharmacovigilance reconciliation Invoice / Budget

Clinical Research Associate : Department neurology of neurology.

CHU de Nimes

2015-9 - 2016-2 · 6 mos

Nimes

International Phase 3 randomized study investigation the safety of levodopa Powder in parkinson's disease: Set Clinical Trial Schedule Pre screening, screening e CRF (clinsight, imedidata) Monitoring Resolving queries Good Clinical Practice